IGF-1 LR3 1mg: Dosage, Reconstitution & Research Protocol Guide

IGF-1 LR3 1mg Vial Specifications

Peptide

IGF-1 LR3 (1 mg Vial) (NNMT inhibitor)

Vial Content

1 mg (1,000 mcg) total peptide

Category

Hormonal / Growth Hormone

Administration Method

Subcutaneous or intramuscular injection

Common Use Case

Muscle hyperplasia, protein synthesis, and recovery

IGF-1 LR3 Mechanism of Action

IGF-1 LR3 is a modified IGF-1 with an arginine-to-glutamic acid substitution at position 3 and a 13-amino acid N-terminal extension. These modifications dramatically reduce binding to IGF binding proteins (IGFBPs), increasing free/active IGF-1 and extending half-life from ~15 minutes to 20–30 hours. It activates the IGF-1 receptor directly in muscle and other tissues, promoting both hypertrophy and hyperplasia.

IGF-1 LR3 Research Findings and Observed Outcomes

Findings and reported areas of study for IGF-1 LR3 (1 mg Vial) include:

• Muscle hyperplasia (new cells)
• Enhanced protein synthesis
• Improved nitrogen retention
• Extended bioavailability

These observations are discussed for research and educational reference only and are not medical claims.

IGF-1 LR3 1mg Supplies for Reconstitution and Handling

• •Insulin syringes (29–31 gauge)
• •Bacteriostatic water or 0.6% acetic acid
• •Alcohol prep pads
• •Sharps container

Supplies listed are for laboratory handling and research preparation purposes only.

IGF-1 LR3 Injection Route, Frequency and Timing

Intramuscular injection into target muscle groups is sometimes studied for localized effects.

IGF-1 LR3 Dosage Ranges

The ranges below pair the listed dose with the draw volume for this product strength.

IGF-1 LR3 1mg Dosage to Syringe Units

Based on reconstitution below

This dosing table is unique to the 1 mg vial. Units refer to markings on a standard U-100 insulin syringe (1 unit = 0.01 mL).

IGF-1 LR3 1mg Duration by Research Dose

At common research doses, one 1 mg vial of IGF-1 LR3 typically supports:

4–6 week cycles with 4-week breaks.

IGF-1 LR3 1mg Reconstitution With Bacteriostatic Water

This section applies specifically to the IGF-1 LR3 (1 mg Vial).

Recommended Diluent

Bacteriostatic water or acetic acid (0.6%)

Diluent Volume

1 mL

Final Concentration

1 mg/mL (1,000 mcg/mL)

IGF-1 LR3 and Compatible Research Pairings

In research settings, IGF-1 LR3 (1 mg Vial) is sometimes paired with peptides such as:

• CJC-1295 + Ipamorelin: GH-axis support alongside direct IGF-1

Use cautiously—IGF-1 LR3 is potent. Do not combine with exogenous GH initially.

Supporting Factors for IGF-1 LR3 Research

Factors recorded alongside this protocol include:

• High-protein diet for muscle synthesis
• Progressive resistance training
• Adequate carbohydrate intake (IGF-1 is insulin-sensitive)
• Quality sleep

These factors can affect how research observations are interpreted.

IGF-1 LR3 1mg Tolerability Notes

IGF-1 LR3 is potent and requires careful dosing.

Some individuals report:

• Hypoglycemia (most significant concern)
• Joint pain
• Jaw/hand growth at high doses
• Organ growth with prolonged use

IGF-1 LR3 1mg Storage Requirements

Unreconstituted

Store frozen at −20°C

Reconstituted

Refrigerate at 2–8°C

Post-Mix Stability

Up to 3–4 weeks (acetic acid diluent improves stability)

This peptide is generally not recommended for:

• Pregnant or breastfeeding individuals
• Active cancer or history of cancer
• Those with hypoglycemia issues
• Anyone advised otherwise by a healthcare professional

IGF-1 LR3 1mg Purchasing and Research Supply Notes

Before ordering IGF-1 LR3 (1 mg Vial), review the product label, available testing documents, and storage instructions.

Check the ResearchLabs listing for:

• Available testing documents
• Product strength and concentration
• Storage and handling instructions
• Current product availability

Confirm the product strength and storage requirements before ordering. Products are for laboratory research only and are not for human consumption.